Meet Gordon A. Brown, DO

Medical School

University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine – Stratford, NJ

Internship & Residency

University of Medicine and Dentistry of New Jersey, School of Osteopathic Medicine – Stratford, NJ

Languages Spoken

English

Ages Served

18+

Board Certified by the American Osteopathic Association, Dr. Gordon Brown completed a Urologic Oncology Fellowship at the UTMD Anderson Cancer Center in Houston, TX. Specializing in the treatment of prostate cancer, Dr. Brown serves as Director of Delaware Valley Urology’s Center for Advanced Therapeutics and Program Director of Urologic Surgery at Rowan University School of Osteopathic Medicine. Dr. Brown has been practicing urology for more than ten years.

SPECIALTIES

  • Benign Prostatic Hyperplasia (BPH)
  • Erectile Dysfunction
  • Kidney Stones
  • Laparoscopic/Robotic Surgery
  • Overactive Bladder (OAB)
  • Prostate Health
  • Urologic Cancers

CHERRY HILL

2090 Springdale Road
Suite D
Cherry Hill, NJ 08003

P: (877) 388-2778

VOORHEES

2401 East Evesham Road
Suite F
Voorhees, NJ 08043

P: (877) 388-2778

WASHINGTON TOWNSHIP

570 Egg Harbor Road
Suite A-1
Sewell, NJ 08080

P: (877) 388-2778

  • Adrenal gland tumor
  • Benign prostatic hyperplasia
  • Erectile Dysfunction
  • General Urology
  • Genitourinary cancer
  • Genital Tract Reconstruction
  • Hematuria
  • Impotence
  • Kidney cancer
  • Kidney stones
  • Kidney tumor
  • Laparoscopic nephrectomy
  • Laparoscopic partial nephrectomy
  • Laparoscopic surgery
  • Laparoscopy
  • Minimally-invasive urologic oncologic surgery
  • Partial cystectomy
  • Partial nephrectomy
  • Prostate cancer
  • Prostate enlargement
  • Radical nephrectomy
  • Radical prostatectomy
  • Renal cell carcinoma
  • Renal mass
  • Renal pelvis robotic repairs
  • Robotic adrenalectomy
  • Robotic nephrectomy
  • Robotic partial nephrectomy
  • Robotic prostatectomy
  • Robotic pyeloplasty
  • Robotic radical nephrectomy
  • Robotic radical prostatectomy
  • Robotic surgery
  • Robotic urologic oncologic surgery
  • Staghorn Calculus
  • Testicular cancer
  • Testicular mass
  • Ureter cancer
  • Ureter robotic repairs
  • Urinary Retention
  • Urologic cancer
  • Urologic tumor
  • Voiding Dysfunction

American Association for Cancer Research
American Society of Clinical Oncologists
American Urological Association
American Medical Association

Patients’ Choice Award (2014)
Readers’ Choice – South Jersey’s Best Physicians (2013)
Top Doc, SJ Magazine (2010)
Top Doc in Urology, South Jersey Magazine (2010)
Readers’ Choice, South Jersey Magazine

Articles in Peer-Reviewed Journals

  • McKiernan J, Donovan MJ, O’Neill V, Bentink S, Noerholm M, Belzer S, Skog J, Kattan MW, Partin A, Andriole G, Brown G, Wei JT, Thompson IM Jr, Carroll P. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol. 2016 Mar 31. doi:10.1001/jamaoncol. 2016: 0097.
  • Donovan MJ, Noerholm M, Bentink S, Belzer S, Skog J, O’Neill V, Cochran JS, Brown GA. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis. 2015 Dec;18(4):370-5. doi: 10.1038/pcan.2015.40. Epub 2015 Sep 8.
  • Badani KK, Thompson DJ, Brown GA, Holmes D, Kella N, Albala D, Singh A, Buerki C, Davicioni E, Hornberger J. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. BJU Int. 2015 Mar;115(3):419-29.
  • Kirin K Syed, Nicole M Harris, Louis H Balsama, Marc A Neff, Gordon A Brown. Impact of Weight Loss on Urologic Disease: A Preliminary Study on ‘Low- T’ MAAUA:2014
  • Hoang AN, Agarwal PK, Walton-Diaz A., Wood CO; Metwalli AR, Kassouf W, Brown GA, Black PC, Urbauer DL, Grossman HB, Dinney CP, Kamat AM. Clinical significance of ureteric “skip lesions” at the time of radical cystectomy: the M.D. Anderson experience and literature review. BJU Int. 2014 May 113(5B):E28-33.
  • Krishnan J, Pietras J, Nachmann M, Brown GA Adult Wilms” tumor with a unique presentation of high-grade fever, photophobia, and headache. Rev Urol. 2012;14(1-2):31-4
  • McGinley KF, Hey W, Sussman, DO, Brown GA Human papillomavirus testing in men. J AM Osteopath Assoc. 2011 Mar; 111 (3 Suppl 2):S26-8
  • Black PC, Brown GA, Dinney CP, Kassouf W, Inamoto T, Arora A, Gallagher D, Munsell MF, Bar-Eli M, McConkey DJ, Adam L Receptor Heterodimerization: a new mechanism for platelet-derived Growth factor induced resistance to anti epidermal growth factor receptor therapy for bladder cancer. J Urol. 2011 Feb; 185(2):693-700
  • Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma Cancer. 2010 Jul 1;116(13):3127-34.
  • Black PC, Shetty A, Brown GA, Esparza-Coss E, Metwalli AR, Agarwal PK, McConkey DJ, Hazle JD, Dinney CP Validating bladder cancer xenograft bioluminescence with magnetic resonance imaging: the significance of hypoxia and necrosis. BJU Int. 2010 Dec;106(11);1799-804
  • Black PC, Dinney CP, Brown GA, Kassouf W, Siefker-Radtke AO
    Munsell MF, Grossman HB, Kamat AM. The role of radical cystectomy in patients with clinical T4b bladder cancer. Urol Oncol. 2011 MarApr;29(2):157- 61.
  • Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at post chemotherapy retroperitoneal lymph node dissection Cancer. 2009 Mar 15;115(6):1310-7.
  • Lipton A, Brown GA, Mundy GR, Roodman GD, Smith MR. New opportunities for the management of cancer-related bone complications Clin Adv Hematol Oncol. 2009 May;7(5 Suppl 11):1-30
  • Hey WD, Shienbaum AJ, Brown GA. Sarcoidosis presenting as an epididymal mass J Am Osteopath Assoc. 2009 Nov;109(11):609-10.
  • Black PC, Brown GA, Dinney CP. The impact of variant histology on the outcome of bladder cancer treated with curative intent.Urol Oncol. 2009 Jan-Feb;27(1):3-7. Epub 2008 Jan 14.
  • Kassouf W, Brown GA, Black PC, Fisher MB, Inamoto T, Luongo T, Gallagher D, Bar-Eli M, McConkey DJ, Adam L, Dinney CP. Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer? J Urol. 2008 Sep;180(3):1146-53. Epub 2008 Jul 18.
  • Kassouf W, Spiess PE, Brown GA, Liu P, Grossman HB, Dinney CP, Kamat AM. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstructionJ Urol. 2008 Jul;180(1):164-7; discussion 167. Epub 2008 May 5.
  • Busby JE, Brown GA, Matin SF. Comparing lymphadenectomy during radical nephroureterectomy: open versus laparoscopic. Urology. 2008 Mar;71(3):413-6.
  • Kassouf W, Agarwal PK, Herr HW, Munsell MF, Spiess PE, Brown GA, Pisters L, Grossman HB, Dinney CP, Kamat AM. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC J Clin Oncol. 2008 Jan 1;26(1):121-6. Doi: 10.1200/JCO.2007.12.9247.
  • Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008 Mar 1;14(5):1478-86.
  • Busby JE, Brown GA, Matin SF. Comparing lymphadenectomy during radical nephroureterectomy: open versus laparoscopic. Urology. 2008 Mar;71(3):413-6.
  • Kassouf W, Spiess PE, Brown GA, Liu P, Grossman HB, Dinney CP, Kamat AM. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. J Urol. 2008 Jul;180(1):164-7; discussion 167.
  • Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, McConkey D, Czerniak B, Dinney CP. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of blasser cancer. J Urol. 2008 Jan;179(1):353-8. Epub 2007 Nov 19. Urology. 2007 Aug;70(2):252-6.
  • Brown GA, Matin SF, Bubsy JE, Munsell MF, Grossman, HB, Dinney CP, Kamat AM. Ability of clinical grade to predict pathologic stage of disease in upper urinary tract transitional cell carcinoma: implications for therapy.
  • Spiess PE, Tannir NM, Brown GA, Liu P, Tu SM, Evans JG, Pisters LL.
    Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at post chemotherapy retroperitoneal lymph node dissection Urology. 2007 Dec;70(6):1173-8.
  • Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, Lin DW. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol. 2007 Dec;178(6):2302-6; discussion 2307.
  • Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, McConkey D, Czerniak B, Dinney CP. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol. 2007 Nov 13;
  • Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-
    Radtke A, Dinney CP, Kamat AM. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol. 2007 Sep;52(3):769-74. 29. Kassouf W, Brown GA, Shetty A, Hazle JD, Stafford RJ, Rosser CJ, Stephens C, Tinkey PT, Pisters LL. An in vivo orthotopic canine model to evaluate distribution of intraprostatic injectate: implications for gene therapy and drug delivery for prostate cancer. Urology. 2007 Oct;70(4):822-5.
  • Shetty AM, Stafford RJ, Elliott AM, Kassouf W, Brown GA, Stephens LC, Tinkey PT, Bidaut L, Pisters LL, Hazle JD. Magnetic resonance imaging assessment of a convective therapy delivery paradigm in a canine prostate model. J Magn Reson Imaging. 2007 Dec; 26 (6): 1672-7
  • Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at post chemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression? Cancer. 2007 Oct 19
  • Bubsy, JE, Brown, GA, Dinney, CPN, Grossman, HB, Pettaway CA, Munsell, MF, Kamat, AM, Matin, SF: Laparoscopic versus traditional
    lymphadenectomy during nephroureterectomy: Is one Approach Superior Urology in press 2007
  • Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-
    Radtke A, Dinney CP, Kamat AM. P0 Stage at Radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors Eur Urol. 2007 Apr 10
  • Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM,
    Kassouf W, Pisters LL. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2007 Jan;177(1):131-8.
  • Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM, Pisters LL. Surgical management of growing teratoma syndrome: The M. D. Anderson cancer center experience. J Urol. 2007 Apr;177(4):1330- 4.
  • Spiess PE, Tuziak T, Tibbs RF, Bassett R, Tamboli P, Brown GA, Grossman HB, Ayala AG, Czerniak B. Pseudosarcomatous and sarcomatous proliferations of the bladder. Hum Pathol. 2007 Feb 15
  • 37. Shrader M, Pino MS, Brown GA, Black P, Adam L, Bar-Eli M, Dinney CP, McConkey DJ. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther. 2007 Jan;6(1):277-85.
  • Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL.: Predictors of outcome in patients undergoing post chemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer. 2006 Oct 1;107(7):1483-1490.
  • Brown GA, Matin SF. Laparoscopic partial nephrectomy: experience in 60 cases.J Endourol. 2007 Jan;21(1):71-4.
  • Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM:.Viable malignant germ cell tumor in the post chemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Cancer 2006 Oct 1;107(7):1503-10.
  • Brown, GA, Matin, SF, Bubsy, JE, Dinney, CPN, Grossman, HB, Pettaway CA, Munsell, MF, Kamat, AM: The ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: Implications for therapy. Urol, In press.
  • Brown, GA, Bubsy, JE, Dinney, CPN, Grossman, HB, Pettaway CA, Munsell, MF, Kamat, AM, Matin, SF: Nephroureterectomy for upper urinary tract transitional cell carcinoma: time to change the treatment paradigm. BJU Int. 2006 Dec;98(6):1176-80.
  • Katona TM, Shienbaum AJ, Wyatt LL, Brown GA, Cheng L. Malignant
    fibrous histiocytoma of the glans penis: a case report. Anal Quant Cytol Histol. 2006 Feb;28(1):39-42.
  • Kassouf, W, Luongo, T, Brown, GA, Adam, L, Gallagher, D, Eve, BY,
    Dinney, CPN: Sequence-dependent efficacy of gefitinib and docetaxel in bladder cancer J Urol. 2006 Aug;176(2):787-92.
  • Spiess, PE, Kassouf, W, Brown, GA, Highshaw, R, Hernandez, M, Kamat, AM, Czerniak, B, Dinney, CPN, Grossman, HB: Early versus delayed urethrectomy: Is there a benefit to either approach? Urology;67(3):466-71, 2006.
  • Bubsy, JE, Brown, GA, Dinney, CPN, Grossman, HB, Pettaway CA, Munsell, MF, Kamat, AM, Matin, SF: Non-Urothelial Tumors of the Upper Urinary Tract: A single center experience and review of the literature. Urology;67(3):518-23, 2006.
  • Kassouf W, Dinney CP, Brown GA, McConkey DJ, Diehl AJ, Bar-Eli M,
    Adam L.Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of
    Gefitinib in bladder cancer cells. Cancer Research 65, 10524-10535,
    November 15, 2005.
  • Jacobsohn K, Ahrar K, Brown GA, Wood CG, and Matin SF. “Is
    radiofrequency ablation safe for solitary kidneys?” J Endourol. 17 (supplement 1):911, 2005.
  • Brown, GA, Santos, R.: Primary aortoesophageal fistula: Surgical Rounds. 2000:397-400.
  • Brown, GA, Ginsberg, PC, Harkaway, RC: Prostatic adenocarcinoma
    diagnosed by prostate-specific antigen analysis of pleural fluid. Urol Int. 1998;60(3):197-8.

Invited Articles

  • 1. McGinley KF, McMahon GS, Brown GA: Impact of the US preventive
    services task force grade D recommendation: Assessment of evaluations for
    elevated prostate-specific antigen and prostate biopsies in a large urology group Rev Urol. 2015; 17(3): 171-177.
  • 2. Donovan MJ, Noerholm M, Bentink S, Belzer S, Skog J, O’Neill V, Cochran JS, Brown GA. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis. 2015 Dec;18(4):370- 5.doi:10.1038/pcan.2015.40. Epub 2015 Sep 8.
  • 3. McGinley K, Brown, GA. Impact of the USPSTF D recommendation:
    Early assessment of referrals for elevated PSA and prostate biopsies in a LUGPA following statement revision. Journal of Clinical Oncology. 2013;31(15).
  • 4. McGinley K, Hey W, Sussman, DO, Brown, GA. Human papillomavirus testing in men. The Journal of the American Osteopathic Association. 2011;111(3 Suppl 2):S26-8.
  • 5. Black, PC, Brown, GA, Dinney, CPN: Clinical and therapeutic significance of aberrant differentiation patterns in bladder cancer. Exp Rev Anti-Cancer Therapy. Expert Rev Anti-cancer Ther. 2007 Jul;7(7):1015-26.
  • 6. Black, PC, Brown, GA, Dinney, CPN: Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol. 2006 Dec 10;24(35):5528-35.
  • 7. Black, PC, Brown, GA, Grossman, HB, Dinney, CPN: Neoadjuvant
    chemotherapy for bladder cancer. World J Urol. 2006 Nov;24(5):531-42.
  • 8. Black, PC, Brown, GA, Dinney CP: Should cystectomy be performed Only at high-volume hospitals by high-volume surgeons? Curr Opin Urol. 2006 Sep;16(5):344-349.
  • 9. Brown, GA, Sussman, DO: A current review of medical therapy for benign prostatic hyperplasia: J Am Osteopath Assoc. 2004 Feb;104(2 Suppl 2):S11-6.

Abstracts

  • 1. Badani K, Brown GA, Rothberg M; The Impact of a 17-gene Genomic
    Prostate Score on Treatment Recommendations for Men with Newly Diagnosed Clinically Low-Risk Prostate Cancer. AUA (Vol 2) 2015 July:181-189: Donovan, MJ, Noerholm, M, Bentink, S, Belzer, S, Skog, J, Brown, GA, Cochran, JS, O’Neill, V: DRE urine exosome gene signature to predict Gleason 7 prostate cancer on an initial prostate needle biopsy. ASCO 2015 Feb: 141579
  • 3. Syed KK, Harris, NM, Balsama LH, Neff MA, Brown GA: Impact Of weight loss on urologic disease: A preliminary study on ‘Low-T’ May 2014:
  • 4. Kassouf W., Black PC, Tuziak t, Bondaruk J, Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, McConkey D, Czerniak B, Dinney CP: Distinctive expression pattern of ErbB family receptors signifies an aggressive varient of bladder cancer: J Urology 2008 Jan; 179(1): 353-8 Epub 2007 Nov. 19.
  • 5. Kassouf W, Brown A Gordon A, Shetty A, Hazle JD, Stafford RJ, Rosser CJ, Stephens C, Tinkey PT, Pisters LL.: An in vivo orthotopic canin model to evaluate distribution of intraprostatic injectate: Implication for gene therapy and drug delivery for prostate cancer: J\Urology, 2007 Oct; 822-5.
  • 6. Philippe E Spiess, Nizar M Tannir, Gordon A Brown, Ping Liu, Ashish M Kamat, Shi-Ming Tu, James G Evans, Louis L Pisters.: Recurrence in patients with PN0 At RPLND: Can we predict which patients are at risk? J. Urol POD34, 90739, May 2007.
  • 7. Philippe E Spiess, Gordon A Brown, Nizar M Tannir, Shi-Ming Tu, Ping Liu, Ashish M Kamat, Christopher G Wood, James G Evans, Louis L Pisters: Predicting disease progression in patients with viable tumor at post chemotherapy RPLND. J. Urol POD30, 90741, May 2007
  • 8. Peter C Black, Jonathan L Wright, Gordon A Brown, Jose A Gomez,
    Michael P Porter, Ashish M Kamat, Colin P.N. Dinney, Daniel W Lin.: Differences in survival between patients with sarcomatoid carcinoma, carcinosarcoma and transitional cell carcinoma of the bladder. J. Urol
    POD47, 93176, May 2007.
  • 9. Piyush K Agarwal, Wassim Kassouf, Colin P. N. Dinney, Mark F. Munsell, Philippe E. Spiess, Gordon A. Brown, H. Barton Grossman, Harry W. Herr, Ashish M. Kamat: TNM Nodal status versus lymph node density for prediction of disease-specific survival after radical cystectomy for bladder cancer J. Urol POD45, 94985, May 2007.
  • 10. Peter C Black, Wassim Kassouf, Gordon A Brown, Ashish M Kamat,
    Graciela M Nogueras, Mark Munsell, Arlene O Siefker-Radtke, Randall E Millikan, H. Barton Grossman, Colin P.N. Dinney.: Variant histology in bladder cancer – Experience in 1246 patients undergoing cystectomy. J. Urol POD42, 96890, May 2007.
  • 11. Spiess, P.E., Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL.: Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal Lymph Node Dissection. J. Urol. 131-8, Jan. 2007.
  • 12. Spiess, P.E., Brown, G.A., Pettaway, C.A., Gomez, J.A., Evans, J., Kassouf, W., Black, P.C., Kamat, A.M., Pisters, L.L.: Malignant transformation of testicular teratoma: A chemo-resistant phenotype. American Urologic Association, J. Urol. MP07, 90885, May 2006
  • 13. Spiess, P.E., Kassouf, W., Brown, G.A., Kamat, A.M., Gomez, J.A., Evans, J., Pisters, L.L.: M. D. Anderson Experience in the Clinical Management of growing teratoma syndrome. American Urologic Association, J. Urol. MP07, 90997, May 2006
  • 14. Kassouf, W., Brown, G.A., Luongo, T., Adam, L., Dinney, C.P.N.: VEGF Modulation is not a predictor for biologic efficacy of gefitinib. American Urologic Association, J. Urol. DP08, 91471, May 2006
  • 15. Kassouf, W., Spiess, P.E., Brown, G.A., Munsell, M.F., Grossman, H.B., Dinney, C.P.N., Kamat, A.M.: Natural history of bladder cancer in patients with P0 disease at radical cystectomy. American Urologic Association, J. Urol. DP18, 91542, May 2006
  • 16. Kassouf, W., Spiess, P.E., Brown, G.A., Munsell, M.F., Grossman, H.B., Dinney, C.P.N., Kamat, A.M.: A Comparison of performance of TNM staging versus lymph node density in risk stratification of patients undergoing cystectomy for urothelial carcinoma. American Urologic Association, J. Urol. DP18, 91546, May 2006
  • 17. Brown, G.A., Black, P.C., Dinney, C.P.N., Adam, L.: Blockade of the platelet derived growth factor receptor may be beneficial in dual therapy of urothelial carcinoma. American Urologic Association, J. Urol. DP08, 93348, May 2006
  • 18. Brown, G.A., Spiess, P.E., Bassett, R.L., Siefker-Radtke, A., Grossman, H.B., Dinney, C.P.N., Kamat, A.M.: Management of primary carcinomas of the male urethra. American Urologic Association, J. Urol. MP07, 93654, May 2006
  • 19. Spiess, P.E., Brown, G.A., Liu, P., Evans, J., Kamat, A.M., Pisters, L.L.: Recurrence pattern and proposed surveillance protocol in patients following post-chemotherapy retroperitoneal lymph node dissection. American Urologic Association, J. Urol. MP11, 94497, May 2006
  • 20. Busby, J.E., Brown, G.A., Matin, S.F.: Efficacy of lymphadenectomy during laparoscopic radical nephroureterectomy: Comparison to the open approach. American Urologic Association, J. Urol. DP14, 94903, May 2006
  • 21. Brown, G.A., Spiess, P.E., Bassett, R.L., Siefker-Radtke, A., Grossman, H.B., Dinney, C.P.N., Kamat, A.M.: Contemporary management of primary carcinomas of the female urethra. American Urologic Association, J. Urol. MP07, 93378, May 2006
  • 22. Lashinger, LM, Brown, GA, Zhu, K, Lu, M, Kwan, T, Cryns, V, McConkey, D. The proteasome inhibitor bortezomib reverses TRAIL :. resistance in refractory human bladder tumors in vivo Proc Amer Assoc Cancer Res 2006;47:.
  • 23. Jacobson KM, Ahrar K, Brown, G.A., Wood CG, Matin SF. Minimally invasive ablative therapy for small renal tumors: The M. D. Anderson experience. 23rd World Congress on Endourology and SWL, J Endourology, 19(S1), MP41-16A, August 2005.
  • 24. Kassouf, W., Luongo, T., Brown, G.A., Adam, L., Gallagher, D., Eve, B.Y., Dinney, C.P.N.: Sequence-Dependent efficacy of gefitinib and ocetaxel in bladder cancer American Urologic Association, J. Urol. DP, 763, May 2005.
  • 25. Luongo, T., Adam, L., Kassouf, W., Brown, G.A., Dinney, C.P.N.: The potential role of clusterin in chemo responsiveness to gemcitabine in bladder cancer cells. Proc Amer Assoc Cancer Res 2005;46,Abst 791
  • Inspira Medical Center (Elmer, Vineland, Woodbury)
  • Jefferson Health New Jersey (Cherry Hill, Stratford, Washington Township)
  • Virtua (Marlton, Voorhees)
  • Aetna HMO
  • Aetna PPO
  • Amerigroup (Medicaid)
  • AmeriHealth (HMO, PPO)
  • AmeriHealth Administrators
  • Cigna
  • Clover Health
  • Coventry & First Health
  • Emblem HIP HMO
  • Empire BCBS
  • Health Net Patient-Centered Community Care Program
  • Health Net Veterans Choice Program
  • Horizon BCBS (Traditional & Managed Care)
  • Horizon BCBS Medicare (Patient Centered HMO)
  • Horizon NJ Health (Horizon NJ TotalCare HMO/SNP)
  • Humana ChoiceCare PPO
  • Independence Blue Cross
  • Keystone Health (AmeriHealth)
  • Magnacare
  • Medicaid
  • Medicare, RR Medicare
  • Oscar (Through Qualcare)
  • Oxford (Liberty & Freedom)
  • Oxford (Metro & Garden State)
  • Qualcare (HMO, POS, PPO, Workers Comp, Community Care)
  • Tricare East
  • Humana Military
  • Tricare 4 Life
  • United Healthcare (Commercial)
  • United Healthcare (Medicare Advantage PPO)
  • US Family Health Plan